Company intelligence / Profile preview
Plexium
San Diego, California, United Statesplexium.com ↗
- Ownership
- Private
- Employees
- ~95
- Development stage
- Preclinical
01
Overview
Plexium has developed a robust preclinical pipeline leveraging its DELPhe platform to discover novel monovalent protein degraders targeting E3 ligases. The company focuses on cancer and other serious diseases but has not yet reported clinical results
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- small molecules (specifically monovalent targeted protein degraders and molecular glues)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Plexium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plexium.